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ABSTRACT
While conjugate vaccines against typhoid fever have recently been recommended by the World Health Organization for
deployment, the lack of a vaccine against paratyphoid, multidrug resistance and chronic carriage all present challenges for
the elimination of enteric fever. In the past decade, the development of in vitro and human challenge models has resulted in
major advances in our understanding of enteric fever pathogenesis. In this review, we summarise these advances, outlining
mechanisms of host restriction, intestinal invasion, interactions with innate immunity and chronic carriage, and discuss
how this knowledge may progress future vaccines and antimicrobials.
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INTRODUCTION
Typhoid and paratyphoid fever are caused by systemic infection
with Salmonella enterica serovars Typhi and Paratyphi A, B or C,
collectively referred to as enteric fever. Of the 14 million cases of
enteric fever per year, 10.9 million are attributed to typhoid, and
3.4 million to paratyphoid (Stanaway et al. 2019). Transmitted
through faecal contamination of food and water, enteric fever
is chiefly endemic in South Asia and Africa. The highest burden
is in children under 14 years of age. In 2017, enteric fever was
estimated to cause 9.8 million disability-adjusted life years and
136 000 deaths (Stanaway et al. 2019).
The species S. enterica is classified into over 2000 serovars
based on their lipopolysaccharide (LPS) and flagellar antigens
(World Health Organization 2007). Many of the virulence fac-
tors required for Salmonella infection are encoded by clusters of
genes known as Salmonella pathogenicity islands (SPIs), which
vary between serovars (Marcus et al. 2000). Enteric fever is most
commonly caused by serovars S. Typhi and S. Paratyphi A.
Salmonella Paratyphi C can also cause enteric fever, as can strains
of S. Paratyphi B unable to ferment the organic compound d-
tartrate (Pinna, Weill and Peters 2016). Human gastroenteritis
and invasive non-typhoidal Salmonella disease are most com-
monly caused by serovars S. Typhimurium and S. Enteritidis
(Gal-Mor, Boyle and Grassl 2014).
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Unlike S. Typhi, S. Typhimurium is not human restricted, and
is able to disseminate systemically in orally challenged mice. It
has therefore frequently been used as a model of enteric fever
(Higginson, Simon and Tennant 2016). In 2010, there were few
clues as to why S. Typhi is restricted to infecting humans. While
a high number of pseudogenes were known to be characteristic
of host-restricted Salmonella genomes (McClelland et al. 2004),
and the capsular Vi polysaccharide produced by S. Typhi to be
immunosuppressive (Wilson et al. 2008), mechanisms by which
host adaptation modifies host–pathogen interactions have only
recently been coming to light. These mechanisms will be dis-
cussed in more detail in later sections and are summarised in
Fig. 1 and Table 1. Furthermore, as each of the typhoidal serovars
underwent genome degradation independently (Didelot et al.
2007; Pinna, Weill and Peters 2016; Nair et al. 2020), clues as to
how S. Paratyphi A is able to cause systemic disease are only
now emerging (Hiyoshi et al. 2018).
The past decade has seen huge advances in our understand-
ing of the pathogenesis of enteric fever. Particularly important
have been development of in vitro typhoid models and human
experimental infection challenge studies, overcoming the lim-
itation of using the genetically distinct S. Typhimurium as a
model pathogen. These research efforts have been paralleled by
urgent vaccine development to control the disease, culminat-
ing in recommendations by the World Health Organization to
deploy new typhoid conjugate vaccines in high-burden regions
of the world. In this review, we discuss advances in the under-
pinning biology, including putative mechanisms of host restric-
tion, the means by which typhoidal serovars manipulate innate
immunity to disseminate systemically, chronic carriage and the
implications for human health.
GASTROINTESTINAL INVASION
Anatomical barriers to infection
Upon ingestion of contaminated food or water by a human
host, S. Typhi faces hostile conditions in the stomach and small
intestinal lumen before invading the terminal ileum (Dougan
and Baker 2014). The very first barrier to infection is gastric acid.
While a high proportion of bacteria are likely killed in the stom-
ach, for those that do survive, the exposure to acid may signal
arrival in a new host, acting as a stimulus for S. Typhi replication
(Ahirwar et al. 2014).
The human gut microbiota, consisting of commensal bac-
teria colonising the gut lumen and mucosa, is thought to play
a key role in defence against pathogen invasion. Unlike S.
Typhimurium, which is able to metabolise butyrate produced
by the microbiota and colonise the intestinal lumen, S. Typhi
and S. Paratyphi A lack the required operon (Bronner et al. 2018).
Despite this, stools rich in transcripts from methane-producing
archaea have been associated with a marginally lower risk of
developing typhoid after human challenge, suggesting that the
microbiome may play a role in enteric fever susceptibility (Zhang
et al. 2018).
Salmonella Typhi must traverse the bactericidal layer of
mucus coating the intestinal wall. Mucus predominantly con-
sists of highly glycosylated proteins called mucins (Johansson
and Hansson 2016). This layer changes dynamically in response
to infection to strengthen the barrier; S. Typhi infection induces
upregulation of secreted gel-forming mucins MUC2 and MUC5B
in an intestinal co-culture model and ex vivo intestinal biopsies,
respectively (Nickerson et al. 2018; Salerno-Goncalves et al. 2018).
In addition to acting as a barrier, the mucus is enriched with
antimicrobial peptides, including α-defensins HD5 and HD6, and
human β-defensins 1 and 2. In intestinal biopsies from human
volunteers administered S. Typhi vaccine strain Ty21a, HD5 mes-
senger RNA (mRNA) was downregulated, potentially represent-
ing a means of immune evasion (Simuyandi and Kapulu 2016).
However, β-defensins, shown to be bactericidal against S. Typhi
in vitro, and protective in mice infected intraperitoneally with
S. Typhi (Maiti et al. 2014), were unchanged. The bactericidal
activity of β-defensins against S. Typhi suggests that antimicro-
bial peptides could have potential as a therapy for antibiotic-
resistant enteric fever. In a Phase 3 trial, antimicrobial pep-
tide surotomycin has been demonstrated as non-inferior to van-
comycin for Clostridium difficile treatment, indicating that such
an approach could be effective against gastrointestinal infec-
tions (Daley et al. 2017). Such a treatment could hypothetically
be used as a prophylactic in outbreak settings or reduce trans-
mission through stool shedding.
In addition to antimicrobial peptides, secretory immunoglob-
ulin A (IgA) is thought to protect the intestinal epithelium by
blocking bacterial uptake and inhibiting flagellar motility (Betz
et al. 2018). The role of secretory IgA in protection against
enteric fever is not yet well characterised. In human chal-
lenge participants, a drop in peripheral B cells and a rise in B
cell α4β7 expression are observed during acute disease, sug-
gestive of gut homing (Toapanta et al. 2016), while oral vac-
cination with attenuated S. Typhi strain Ty21a significantly
increases S. Typhi-specific stool IgA (Arya and Agarwal 2014).
Serum Vi IgA is associated with protection in Vi-polysaccharide-
vaccinated human challenge participants (Dahora et al. 2019),
but no relationship has been elucidated between gut IgA and
protection against enteric fever. Interestingly, mice lacking the
polymeric immunoglobulin receptor required for IgA transport
to the intestinal lumen are significantly more resistant to S.
Typhimurium infection (Betz et al. 2018), although the poten-
tial reasons for this are numerous—possibly due to changes in
the microbiome, compensation by serum antibodies or IgG, or
reduced M-cell-mediated uptake—and may act in combination.
Underneath the mucus layer, the glycocalyx, composed of
glycolipids and glycoproteins extending from the plasma mem-
brane of intestinal epithelial cells, serves as an additional pro-
tective barrier. Salmonella Typhimurium uses two glycosyl hydro-
lases, nanH and malS, to degrade the glycocalyx, without which
it is cannot efficiently invade (Arabyan et al. 2016). While the
typhoidal serovars do not possess nanH, malS is present in S.
Typhi, S. Paratyphi A and S. Paratyphi B with over 97% sequence
identity (UniProt 2019).
Invasion of the intestinal epithelium
At the surface of the intestinal epithelium, S. Typhi attaches
to epithelial cells using fimbriae (Berrocal et al. 2015) (Fig. 2),
extracellular protein structures that mediate bacterial adhe-
sion to epithelial cells. Fimbriae may play a role in host speci-
ficity: recombinant Escherichia coli expressing S. Typhi fimH is
only able to strongly bind human epithelial cells, whereas E.
coli expressing fimH from porcine-, bovine- and avian-adapted
Salmonella serovars specifically binds cells from their respective
hosts (Yue et al. 2017). Escherichia coli expressing S. Typhimurium
fimH weakly binds cells from a variety of hosts at equal affinity,
possibly reflecting its niche as a non-invasive broad-specificity
serovar. While fimH is shared with high homology between
Salmonella serovars, including S. Paratyphi A, B and C, single-
nucleotide polymorphisms in this gene are sufficient to change
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Figure 1. Hypothesised mechanisms of host restriction. (A) Salmonella Typhi fimbriae are specific for adhesion to human epithelial cells, while S. Typhimurium fimbriae
can adhere to cells from a variety of hosts. (B) Salmonella Typhimurium produces bacterial effector GtgE that cleaves Rab32, preventing killing in mouse macrophages.
Salmonella Typhi lacks GtgE and is therefore killed in mouse macrophages. (C) Salmonella Typhi is more susceptible to iron starvation than S. Typhimurium in vitro and
in mice, and therefore is only able to infect iron-overloaded mice. (D) The typhoid toxin is secreted by intracellular bacteria into the Salmonella-containing vacuole and
transported to the extracellular space. Here, it binds to target cell receptors (PODXL on epithelial cells, CD45 on macrophages and T and B cells; Galán 2016). The toxin
preferentially binds to glycans terminated by Neu5Ac, characteristic of human cells. In the nucleus of target cells, the DNase activity of the toxin causes DNA damage
and cell cycle arrest.
Table 1. Summary of the evidence as to why S. Typhi is invasive in humans but not mice, and why S. Typhimurium is invasive in mice but not
humans.
Mice Humans
S. Typhi Non-invasive Invasive
S. Typhi lacks gtgE to break down Rab32 in mice The action of the typhoid toxin is human specific
S. Typhi is susceptible to iron starvation in mice S. Typhi FimH specifically binds human cells
S. Typhi evades innate immune responses at the
intestinal epithelium
S. Typhi counters Rab32 in humans using the
SPI-1-encoded type III secretion system
S. Typhimurium Invasive Non-invasive
S. Typhimurium is less susceptible to iron
starvation
S. Typhimurium FimH only weakly binds human cells
S. Typhimurium produces gtgE to break down
Rab32
Induces an innate immune response at the intestinal
epithelium and inflammatory diarrhoea
In the high osmolarity environment of the intestinal lumen,
the bacterial sensor kinase EnvZ phosphorylates the down-
stream regulator OmpR (Nuccio, Rüssmann and Bäumler 2010).
This in turn supresses S. Typhi expression of TviA, a key reg-
ulatory protein encoded within the viaB operon of the serovar-
specific SPI-7 locus (Nuccio, Rüssmann and Bäumler et al. 2010)
(Fig. 3). Low levels of TviA result in expression of type III secre-
tion system 1 (T3SS1), a needle-like protein complex used to
inject Salmonella effectors into the host cytosol, and flagellin,
thus allowing invasion of the intestinal epithelium (Nuccio,
Rüssmann and Bäumler 2010). High osmolarity also induces S.
Typhi to express SPI-9, enhancing adherence to epithelial cells
(Velásquez et al. 2016). It has long been thought that S. Typhi
targets specialised antigen-sampling epithelial cells known as
M cells for invasion (Dougan and Baker 2014). However, it lacks
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Figure 2. Invasion of the intestinal epithelium by S. Typhi. Salmonella Typhi invasion is impeded by mucus and the glycocalyx acting as physical barriers, as well as the
action of defensins, cathelicidins and IgA in the intestinal mucosa. Those bacteria that successfully adhere to the epithelium using fimbriae cross by T3SS-1- or STIV-
mediated invasion of intestinal epithelial cells. Bacteria in the lamina propria and subepithelial dome (SED) are then phagocytosed and systemically disseminated to
the liver and spleen via the blood and lymph.
Figure 3. Genetic regulation in response to changes in osmolarity. In the high osmolarity intestinal lumen, EnvZ auto-phosphorylation activity is high, ultimately
resulting in the phosphorylation of OmpR and suppression of the viaB locus. Thus, Vi capsule biosynthesis is supressed, while T3SS-1 and flagellin expression can
take place. In the lower osmolarity environment inside cells, EnvZ undergoes a conformational change that reduces auto-phosphorylation. The viaB locus is hence
expressed, resulting in synthesis of TviA and the Vi capsule. Regulatory protein TviA then goes on to supress T3SS1 and flagellin expression. Under high osmolarity
conditions, SPI-9 is also transcribed by a mechanism dependent on rpoS.
cells, and in fact appears to preferentially invade enterocytes in
a co-culture model and in ex vivo biopsies (Gonzales, Wilde and
Roland 2017; Nickerson et al. 2018). Nonetheless, this question is
difficult to resolve fully due to the high numbers of enterocytes
in the intestinal epithelium relative to M cells, and the inability
to follow gastrointestinal infection in vivo in humans.
The chief mechanism of Salmonella epithelial invasion is
mediated by T3SS-1, a molecular needle encoded by the rel-
atively conserved SPI-1 locus (Sabbagh et al. 2010). Salmonella
Typhimurium injects effector proteins SipA, SipC, SopE and
SopE2 into the host cytosol. The effectors activate Rho-family
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dynamics (Hodge and Ridley 2016). This results in cytoskeletal
rearrangement so as to engulf S. Typhimurium. Surprisingly, the
effector protein SopE2 inhibits epithelial cell invasion (Valen-
zuela et al. 2015). In S. Typhimurium the bacterial ubiquitin ligase
SopA counteracts the inhibitory effect of SopE2, allowing inva-
sion to take place but also inducing interleukin-8 (IL-8) secretion
(Valenzuela et al. 2015). In S. Typhi both SopA and SopE2 are pseu-
dogenes, allowing it to invade cells while avoiding production of
IL-8. Salmonella Paratyphi A, however, possesses SopE2 but not
SopA (Johnson, Mylona and Frankel 2018). Like S. Typhimurium,
S. Typhi infection induces the enterocyte cytoskeleton to pro-
trude at sites of invasion (Nickerson et al. 2018). Reacting to
invasion by S. Typhi, enterocytes downregulate genes involved
in cytoskeleton remodelling (Nickerson et al. 2018). This may
represent a host response to prevent further infection, as phar-
macological inhibition of actin or microtubule assembly almost
entirely blocks S. Typhi uptake.
To avoid excessive Rho-family GTPase stimulation, which
would lead to the activation of NF-κB and inflammatory gene
expression (Winter et al. 2014), S. Typhimurium effector SptP
reverses these changes to the cytoskeleton, while the effector
AvrA blocks nuclear translocation of NF-κB subunit p65 (Collier-
Hyams et al. 2002). In S. Typhi, however, a different strategy is
required, as the gene encoding AvrA is absent and its trans-
lated SptP protein is too unstable to be secreted. Rather, sens-
ing the drop in osmolarity as it enters the cell, S. Typhi upreg-
ulates TviA, resulting in concomitant downregulation of T3SS-
1 (Nuccio, Rüssmann and Bäumler 2010). By doing so, exces-
sive Rho-family GTPase stimulation is avoided, preventing the
associated induction of NF-κB signalling (Winter et al. 2014). It
is unclear which of these strategies is more successful: whereas
S. Typhi induces greater NF-κB responses than S. Typhimurium
in infected Henle-407 cells, in ex vivo infected intestinal biopsies
the opposite appears to be true (Hannemann and Galán 2017;
Nickerson et al. 2018). Unlike S. Typhimurium, S. Typhi does not
induce activation of STAT3, a transcription factor that upreg-
ulates IL-10 in response to S. Typhimurium infection (Hanne-
mann and Galán 2017; Jaslow et al. 2018). This is likely due to
the lack of SopE2 (Ruan et al. 2017) and SarA (Jaslow et al. 2018)
in S. Typhi. Although T3SS-1-dependent invasion is well charac-
terised, S. Typhi is also able to invade epithelial cells via bacte-
rial outer membrane protein STIV, binding the receptor tyrosine
kinase Met to induce uptake (Chowdhury et al. 2019). Both the
typhoidal and non-typhoidal Salmonella serovars possess STIV
(UniProt 2019).
Having passed through the epithelium, S. Typhimurium flag-
ellin activates toll-like receptor (TLR)-5 at the basolateral sur-
face, giving rise to neutrophil recruitment and inflammatory
diarrhoea (Keestra-Gounder, Tsolis and Bäumler 2015). In S.
Typhi, however, the additional role of TviA in mediating down-
regulation of flagellin limits TLR-5 recognition, as well as acti-
vating biosynthesis of the protective Vi polysaccharide capsule.
Infection of human colonic explants with wild-type S. Typhi elic-
its lower levels of IL8 expression relative to a tviA S. Typhi strain
(Raffatellu et al. 2005). It may be this upregulation of the Vi cap-
sule as the bacterium crosses the intestinal barrier that renders
it immediately susceptible to immunoglobulins induced by Vi-
based typhoid vaccines.
Although S. Typhi is able to pass through the epithelium
without causing inflammatory diarrhoea, there is evidence to
suggest a host cytokine response occurs at this point. In a co-
culture model of the intestinal epithelium, IL1β, IL17A, TNF-
α, IL6, CCL3 and IL8 were released in response to S. Typhi
infection (Salerno-Goncalves et al. 2019). Although secretion
of TNF-α, IL6 and CCL3 was reduced in the absence of
macrophages, of these three cytokines only TNF-α was directly
produced by macrophages in response to stimulation, suggest-
ing that macrophages may modulate cytokine secretion by other
cells in the intestinal mucosa. Salmonella Paratyphi B induced
greater secretion of IL6 and TNF-α than S. Paratyphi A or S. Typhi,
while S. Paratyphi A induced greater secretion of CCL3 (Salerno-
Goncalves et al. 2019). Despite possessing the viaB locus, S. Typhi
still stimulated IL8 secretion from the fibroblasts, endothelial
and epithelial cells in the model, as did S. Paratyphi A and B
(Salerno-Goncalves et al. 2018, 2019). This may indicate that IL8
release is dampened down but still significant, or that the Vi cap-
sule was poorly expressed under these culture conditions. Like-
wise, there was a trend towards apical IL8 secretion by intesti-
nal biopsies in response to S. Typhi, as well as significant api-
cal secretion of IL10, IL2 and IL4 (Nickerson et al. 2018). How-
ever, there was no significant cytokine release at the basolat-
eral side, which could account for the lack of neutrophil infil-
tration in typhoid fever. Dose-dependent induction of plasma
cytokines sCD40L, fractalkine, GROα, IL1RA, EGF and VEGF is
observed in typhoid challenge participants within 12 h of chal-
lenge, the period in which intestinal invasion is expected to take
place; however, the origin of this signal is as yet unconfirmed
(Blohmke et al. 2016).
This stage of infection likely represents the point at which
antibodies induced by mucosal vaccines target invading S. Typhi,
and there is increasing evidence that parenteral vaccines can
also induce protective mucosal responses (Clements and Freytag
2016). Subcutaneous vaccination with STIV has been shown to
protect iron-overloaded mice from death following S. Typhi and
S. Paratyphi A challenge, and is therefore an attractive target for
a bivalent vaccine. The role of T3SS-1 effector proteins in inva-
sion also renders them potential targets: vaccination with SipD
for example, which controls assembly of the T3SS and is shared
by S. Typhi, S. Paratyphi A and S. Typhimurium, is capable of
protecting orally vaccinated mice against S. Typhimurium chal-
lenge (Fasciano et al. 2019). Likewise, subunit vaccines composed
of SipB/SipD or SseB/SseC constructs, effectors shared between
serovars, have also proved effective in protecting mice against S.
Typhimurium challenge (Fasciano et al. 2019).
In summary, to invade the intestinal epithelium S. Typhi
must first survive gastric acid exposure, evade antimicrobial
peptides in the mucus and break down the glycocalyx. Upon
reaching the epithelium, S. Typhi can then use its fimbriae to
attach to enterocytes, and induce uptake using T3SS-1 or STIV.
To avoid immune activation via Rho-family GTPase stimulation
or TLR-5, the TviA locus allows S. Typhi to respond to changes in
osmolarity by downregulating T3SS-1 and flagellin, and upregu-
lating the immunomodulatory Vi capsule.
INTERACTION WITH INNATE HOST DEFENCES
Dissemination via mononuclear phagocytes
Although S. Typhi DNA has been detected in the blood of human
challenge participants in the first 24 h following challenge (Dar-
ton et al. 2017), there is currently no direct evidence to show
how S. Typhi disseminates systemically to the spleen and liver
in humans. Mouse models using S. Typhimurium suggest dis-
semination is mediated by migration of infected mononuclear
phagocytes from the intestine into the blood or lymph (Vazquez-
Torres et al. 1999). Pseudogenisation of bacterial effector SseI,
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S. Typhimurium sequence type ST313, enhances systemic dis-
semination of S. Typhimurium in orally challenged mice due to
increased uptake by CD11b+ migratory dendritic cells (Carden
et al. 2017).
In order to achieve dissemination within mononuclear
phagocytes, S. Typhi must evade detection and killing by these
cells. Although S. Typhi can be phagocytosed, uptake of S. Typhi
and S. Paratyphi A is reduced in the absence of functional flag-
ella (Elhadad et al. 2015; Schreiber et al. 2015) and fimbriae (Berro-
cal et al. 2015), suggesting that phagocytes can also be actively
invaded. During entry to these cells the S. Typhi Vi capsule
has a variety of immunomodulatory effects. Vi masks LPS from
recognition by TLR-4 on the cell surface, preventing subsequent
release of inflammatory cytokines TNF-α, IL6 or IL8 (Wilson et al.
2008), and reduces phagocytosis-mediated by BPI, an antimicro-
bial protein that binds LPS (Balakrishnan, Schnare and Chakra-
vortty 2016). Despite the absence of Vi, the percentage of IL8+
macrophages following stimulation with S. Paratyphi A and B
is no greater than after stimulation with S. Typhi, suggesting
that these serovars may possess alternative mechanisms to sup-
press IL8 secretion (Salerno-Goncalves et al. 2019). For example,
although S. Paratyphi A LPS is exposed and capable of bind-
ing TLR-4, it does not activate it, acting as a competitive TLR-4
inhibitor in the presence of S. Typhimurium LPS (Chessa et al.
2014).
Having formed a vacuole within the cells, in order to sur-
vive S. Typhi needs to avoid host-derived reactive oxygen and
nitrogen species. In the absence of TLR-4-mediated NF-κB acti-
vation the transcription of inducible nitric oxide synthase is
reduced, limiting synthesis of bactericidal nitric oxide (Wilson
et al. 2008). The acidic environment of the Salmonella containing
vacuole induces expression of SPI-2, allowing S. Typhimurium
to prevent NADPH oxidase assembly on the phagosome mem-
brane and evade killing (Gallois et al. 2001; Liew et al. 2019).
While SPI-2 deletion does reduce the virulence of S. Paraty-
phi A when injected into the peritoneum of mice, ability to
colonise the liver and spleen is retained (Yin et al. 2020). In
S. Typhi, knock out of SPI-2 has no effect on survival within
human macrophages (Forest et al. 2010). The redundancy could
in part be due to deterioration of epithelial invasion regula-
tor marT into a pseudogene in S. Typhi, creating a new open
reading frame that appears to encode a novel H2O2-protective
protein (Ortega et al. 2016). Furthermore, a eukaryote-like ser-
ine/threonine kinase unique to S. Typhi is induced in response to
H2O2, promoting survival within macrophages and contributing
to virulence in infected mice (Theeya et al. 2015). As inhibitors
of eukaryotic serine/threonine kinases are already approved as
cancer treatments, the eukaryote-like serine/threonine kinase
unique to S. Typhi may be an attractive therapeutic target, ren-
dering the bacteria more susceptible to killing by H2O2 (Kan-
naiyan and Mahadeva 2017). The suf operon, involved in produc-
ing Iron-Sulphur clusters under oxidative stress, also appears
to contribute to S. Typhi survival within macrophages (Wang
et al. 2015). Within monocyte-derived dendritic cells, S. Typhi
switches from carbohydrate to lipid consumption (Xu et al.
2019). The significance of this is not yet understood, although
for S. Typhimurium lipid metabolism is necessary for replica-
tion within pro-inflammatory macrophages (Reens, Nagy and
Detweiler 2020).
Within macrophages, S. Typhi must also avoid killing medi-
ated by host protein Rab32 (Spano and Galán 2012). Although
the mechanism of killing has not yet been elucidated, Rab32 is
involved in the delivery of cargo to lysosome-related organelles,
and therefore may allow delivery of antimicrobial proteins
to the Salmonella containing vacuole (Spano and Galán 2012).
While S. Typhimurium produces the protease gtgE, allow-
ing it to break down Rab32 and therefore survive in mouse
macrophages, S. Typhi does not, resulting in rapid killing. In
human macrophages, however, S. Typhi is instead thought to
counter this pathway though a mechanism dependent on its
SPI-1-encoded T3SS1 (Baldassarre et al. 2019).
Rather than being killed, internalised Salmonella can induce
macrophage death; however, it is as yet unknown whether this
acts to benefit the bacteria or the host. For S. Typhimurium,
bacterial effector protein SipB activates caspase-1, resulting
in a rapid and inflammatory cell death known as pyroptosis
(Chen et al. 2015). SipB knockout reduces the virulence of S.
Typhimurium in mice, and is also present in the typhoidal
Salmonella serovars (Chen et al. 2015; UniProt 2019). In addi-
tion to direct activation by bacterial effectors, recognition of
S. Typhimurium flagellin by sensor protein NAIP activates the
NLRC4 inflammasome, a multiprotein complex that induces
caspase-1 activation (Kortmann, Brubaker and Monack 2015;
Winter et al. 2015; Brewer, Brubaker and Monack 2019). This
suggests that S. Typhimurium-induced cell death could in fact
represent a protective host response. The temporal association
between pyroptosis and S. Typhimurium clearance has led to
the suggestion that bacterial release from dying macrophages
leaves S. Typhimurium vulnerable to uptake and killing by neu-
trophils (Miao et al. 2010). This has been confirmed by mouse
experiments finding that caspase-1 knockout reduces bacte-
rial clearance by neutrophils and increases susceptibility to S.
Typhimurium (Broz et al. 2012). Although S. Typhi flagellin is
a particularly potent NLRC4 activator (Yang et al. 2014), the
TviA-dependent downregulation of flagellin appears to reduce
NLRC4 activation and pyroptosis, potentially acting as a means
of immune evasion (Winter et al. 2015). In contrast, typhoidal
serovar S. Paratyphi A induces a high level of macrophage killing
(Salerno-Goncalves et al. 2019).
During acute disease the level of iron-regulating hormone
hepcidin is significantly raised in the serum, resulting in the
sequestration of iron within macrophages (Darton et al. 2015).
Iron starvation is an important mechanism of host defence, as
illustrated by the susceptibility of iron-overloaded mice to S.
Typhi infection (Das et al. 2019). This raises the possibility of
sequestering iron from S. Typhi as a feasible strategy for treat-
ment. While small molecule iron chelators such as desferriox-
amine can be utilised by S. Typhi and therefore enhance growth,
iron chelating polymers too large to be accessible to bacteria
are capable of suppressing Staphylococcus aureus wound infec-
tions in mice (Parquet et al. 2018). While diversion of iron to
macrophages in acute disease might restrict the growth of free
bacteria, it could be advantageous to bacteria residing intracel-
lularly. As well as being required for bacterial growth, iron acti-
vates S. Typhi ferric uptake regulator (Fur), repressing sRNAs
RfrA and RfrB, and enhancing H2O2 resistance and intracellular
survival through an unknown mechanism (Leclerc, Dozois and
Daigle 2013). It has more recently been found that in the case of
S. Typhimurium infection in Raw264.7 cells, hepcidin increases
iron in the cytosol but decreases it in the Salmonella-containing
vacuole (Lim, Soo Kim and Jeong 2018). Rather than starving S.
Typhimurium, the lack of iron impairs production of bactericidal
reactive oxygen species and results in a higher bacterial load in
mice.
To summarise, following invasion S. Typhi is thought to be
taken up by mononuclear phagocytes, through which it dissem-
inates systemically in a primary bacteraemia. Evasion of killing
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Figure 4. Complement evasion by S. Typhi and S. Paratyphi A. The alternative
and classical complement pathways culminate in the formation of C3 and C5
convertases, resulting in the attraction of neutrophils by C5a and opsonisation by
C3b. In S. Typhi expression of the Vi capsule and absence of very long O-antigen
chains prevents C3b and IgM deposition, while in S. Paratyphi A the production
of very long modified O-antigens prevents IgM binding shorter O-antigen chains
on its surface. Furthermore, the surface protease PgtE cleaves C3b, C4b and B.
and shielding LPS from TLR-4 to prevent iNOS transcription are
important to allow S. Typhi to survive host defences. By down-
regulating flagellin expression, S. Typhi is able to prevent its host
cell undergoing pyroptosis, averting the resultant inflammation
and uptake by neutrophils.
Evading complement-dependent neutrophil activation
The considerable efficacy of the T cell-independent Vi polysac-
charide vaccine (Milligan et al. 2018) and the association between
baseline LPS antibody and resistance to S. Paratyphi A in
human challenge (Dobinson et al. 2017) suggests that at some
stages during the course of infection, these typhoidal Salmonella
bacteria must be extracellular, and therefore vulnerable to
opsonisation. However, S. Typhi appears to have evolved sev-
eral mechanisms to evade complement-dependent opsonisa-
tion and killing (Fig. 4): shielding by the Vi capsule, LPS modifi-
cation and breakdown of complement components by PgtE. The
lack of free hydroxyl groups in the Vi capsule prevents C3b from
binding the bacterial surface (Wilson et al. 2011). In the absence
of Vi-specific antibodies, the Vi capsule also reduces IgG, C3 and
membrane attack complex binding (Hart et al. 2016). This pro-
tection is enhanced by a nonsense mutation in the fepE gene,
preventing synthesis of very long O-antigen chains that would
expose hydroxyl groups to C3b at the capsule surface (Craw-
ford et al. 2013). In addition, S. Typhi shares an operon with S.
Typhimurium that glucosylates the O-antigen on LPS to reduce
C3 binding (Riva, Korhonen and Meri 2015). Conserved surface
protease PgtE is present in both typhoidal and non-typhoidal
serovars, and cleaves C3b, C4b and B (Kintz et al. 2017; UniProt
2019). Therapeutically, it is possible that Salmonella could be
rendered more susceptible to complement by inhibition of the
complement-cleaving protease PgtE. In silico docking of FDA-
approved protease inhibitors suggested that the antiretroviral
drug indinavir bound PgtE with the highest affinity (Samykannu
et al. 2018). However, this finding has not yet been validated
experimentally. While S. Paratyphi A lacks the Vi capsule and
produces functional fepE, the O-antigen of S. Paratyphi A dif-
fers due to the pseudogenisation of rfbE, giving it a branching
paratose residue that prevents IgM-mediated activation of the
classical complement pathway (Hiyoshi et al. 2018).
Despite correlating with disease attenuation, serum bacte-
ricidal antibody has not been found to associate with protec-
tion in the human challenge model to date (Juel et al. 2018).
This raises the possibility that the direct role of complement
in S. Typhi lysis is secondary to its role in attracting and acti-
vating phagocytes. Inhibition of complement deposition by fac-
tors such as the Vi capsule reduces generation of chemoat-
tractant C5a, impairing neutrophil recruitment (Wangdi et al.
2014). However, in the presence of vaccination-induced antibod-
ies against the Vi capsule, neutrophil phagocytosis of Vi-coated
beads is increased, particularly in participants who remained
healthy following subsequent S. Typhi challenge (Celina et al.
2021). Therefore, vaccination may act to overcome this method
of evasion. Although peripheral blood neutrophil counts drop in
acute disease, the peripheral blood transcriptome is dominated
by clusters associated with neutrophils, suggesting a significant
involvement in the immune/inflammatory response (Wadding-
ton et al. 2014; Blohmke et al. 2016). Calprotectin, a chelating pro-
tein complex that constitutes 40% of neutrophil cytosol, is raised
in both the plasma and faeces of patients with typhoid fever,
and is able to inhibit the growth of S. Typhi in vitro (De Jong et al.
2015). As in macrophages, neutrophil phagocytosis of S. Typhi or
S. Paratyphi A fails to stimulate a bactericidal oxidative burst by
NADPH oxidase (Hiyoshi et al. 2018), although it is not currently
clear whether this is sufficient to suppress killing by neutrophils.
Overall, it appears that S. Typhi and S. Paratyphi A have
undergone convergent evolution in order to evade complement
binding, preventing chemo-attraction of neutrophils and there-
fore oxidative killing. The analogous role of S. Paratyphi LPS to
the Vi capsule in immune evasion supports the pursuit of this
antigen as an S. Paratyphi A vaccine target. While S. Paraty-
phi C also produces the protective Vi capsule, the mechanism
by which typhoidal strains of S. Paratyphi B evade complement
remains elusive.
Natural killer cell stimulation
While the role of natural killer (NK) cells is well established in
viral and cancer immunity, a contribution to bacterial immu-
nity has come to light more recently. In mice infected with S.
Typhimurium, IL18-mediated recruitment of NK cells to the gut
did not affect bacterial load, but did increase intestinal inflam-
mation (Müller et al. 2016). Although gastrointestinal inflamma-
tion is not a hallmark of human enteric fever as it is in mice,
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Figure 5. Chronic carriage of S. Typhi in the gallbladder. Bile induces S. Typhi to
upregulate SPI-1 genes, resulting in invasion of the gallbladder epithelium. Flag-
ellin allows S. Typhi to bind to gallstones and forms a scaffold to which further
bacteria can bind. The extracellular matrix consists of curli fimbriae, Vi antigen,
O-antigen and extracellular DNA.
Jong et al. 2017). Furthermore, in participants receiving attenu-
ated oral vaccine S. Typhi strain Ty21a, gene sets relating to NK
cells were enriched in the whole-blood transcriptome (Blohmke
et al. 2017). In vitro stimulation of NK cells with fixed S. Typhi
enhanced expression of activation marker CD69 as well as their
killing ability, while stimulation with attenuated vaccine strains
Ty21a and M01ZH09 increased the proportion of CD107a and
interferon-γ -positive NK cells (Puente et al. 2000; Blohmke et al.
2017). However, it is yet to be determined whether NK cells play
a role in immunity to enteric fever in vivo.
THE CARRIER STATE
Following the resolution of acute enteric fever, 2–5% of those
infected with S. Typhi are thought to progress to an asymp-
tomatic carrier state, where S. Typhi persists in the gallblad-
der and is intermittently shed in the stool (John et al. 2014)
(Fig. 5). Both S. Typhi and S. Paratyphi A have been recovered
at a high bacterial load from the gallbladders of patients under-
going cholecystectomy in Nepal (Dongol et al. 2012). The pres-
ence of bile induces transcriptional changes in S. Typhi, result-
ing in upregulation of the anti-oxidative enzymes superoxide
dismutase and catalase by a mechanism dependent on quorum
sensing (Walawalkar, Vaidya and Nayak 2016). Bile also induces
S. Typhi, but not S. Typhimurium, to upregulate SPI-1 genes,
increasing invasion of the gallbladder epithelium (Byrne et al.
2018). Interestingly, while typhoidal Salmonella serovars invade
the gut without inducing neutrophil infiltration, Salmonella-
positive (24 S. Typhi, 22 S. Paratyphi A and 2 S. enterica group C)
gallbladders from cholecystectomy patients had a greater rate of
neutrophil infiltration than culture-negative or non-Salmonella
culture-positive gallbladders (Dongol et al. 2012).
Gallstones are a major risk factor for chronic carriage, affect-
ing an estimated 90% of carriers (Lovane et al. 2016). Despite car-
riers tending to be asymptomatic, chronic carriage of S. Typhi
and S. Paratyphi A each induce distinct plasma metabolome sig-
natures, although the significance of this is unclear and has not
yet been validated in an independent cohort (Näsström et al.
2018). Both S. Typhi and S. Typhimurium form biofilms on the
surface of cholesterol gallstones in the presence of bile, giving
rise to a thick, loosely packed cell matrix connected by a web
of proteins, polysaccharides and extracellular DNA (Adcox et al.
2016). This process is dependent on both quorum sensing, allow-
ing the bacteria to sense their population density, and flagellae,
which allow attachment to the gallstone and provide a scaffold
to which other bacteria can bind (Prouty, Schwesinger and Gunn
2002; Crawford et al. 2010). Biofilms can be directly visualised by
electron microscopy on the surface of gallstones from human S.
Typhi carriers, and are thought to render the bacteria resistant
to antibiotic treatment (Crawford et al. 2010).
Although the Vi antigen is not necessary for biofilm forma-
tion, it does constitute part of the extracellular biofilm matrix
(Adcox et al. 2016). Among those infected with S. Typhi, carriers
constitute the few who raise substantial Vi antibody responses
(Dougan and Baker 2014). The typhoid toxin, a multi-subunit
exotoxin that induces cell cycle arrest (Galán 2016), does not
play an obvious role in acute disease (Gibani et al. 2019), but may
instead play a role in chronic disease. Transgenic expression of
the typhoid toxin by S. Typhimurium results in development of a
long-term asymptomatic infection in the liver following murine
challenge (Del Bel Belluz et al. 2016).
As chronic carriers may act as a reservoir for infection, and
therefore provide a barrier in the elimination of enteric fever,
innovative strategies will be necessary to identify and treat carri-
ers. At present, carriers are identified on the basis of Vi seropos-
itivity, which has a low positive predictive value and will not
be discriminatory in a vaccinated population, or bacterial shed-
ding, which is intermittent (Näsström et al. 2018). The presence
of a unique plasma metabolome signature in carriers presents
a potential alternative avenue of diagnostics (Näsström et al.
2018). As S. Typhi biofilms are generally antibiotic resistant, car-
riers are currently treated by surgical removal of the gallblad-
der. Treatment of carriers with biofilm modulators, currently
under development to treat hospital-acquired infections, might
represent a less invasive alternative (Vila, Moreno-Morales and
Ballesté-Delpierre 2020). As S. Typhi biofilm formation appears to
be dependent on quorum sensing, the use of acyl-homoserine
lactonases to disrupt these signals may also hold potential.
Finally, if the typhoid toxin emerges as a major player in chronic
disease, monoclonal antitoxins could be an attractive treatment.
CONCLUSION
Typhoidal Salmonella serovars are characterised by human
restriction, and an ability to evade immune detection and dis-
seminate systemically. Binding specificity of the typhoid toxin
and fimbriae to human cells may explain how S. Typhi is able
to cause disease in humans, while iron restriction or detection
by Rab32 may explain why S. Typhi is less adept at infecting
non-human hosts. These insights into host restriction are con-
tributing to the development of relevant animal models, which
will accelerate preclinical development of vaccines and novel
antimicrobials. Following invasion of the intestinal epithelium,
while S. Typhi is able to evade detection by TLR4, the classical
complement pathway and oxidative killing through production
of the Vi capsule, adaptations in the LPS structure of S. Paraty-
phi A have enabled it to do the same. Knowledge of the virulence
factors necessary to establish systemic disease presents an array
of potential vaccine and therapeutic targets. While Vi-based vac-
cines have proved efficacious against S. Typhi, no vaccine is cur-
rently licensed against S. Paratyphi A. It is not currently known
whether serovar replacement following widespread S. Typhi vac-
cination is a valid concern, but regardless it is likely that S.
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fever cases in future. As such, development of a bivalent vac-
cine would be hugely beneficial to public health in Asia, where
the two infections are co-endemic. This review also highlights
several virulence factors shared with S. Typhimurium, potential
targets of bi- or trivalent vaccines against invasive Salmonella dis-
ease in Africa. Furthermore, as extensively drug-resistant infec-
tions rise, novel therapeutic strategies will be needed to treat
infections. The pathogenesis of S. Paratyphi B- and C-mediated
enteric fever remains a mystery, but currently presents a less
pressing global health concern. Despite a chiefly unicellular
lifestyle, typhoidal Salmonella is able to form a multicellular com-
munity on the surface of gallstones and persist long term in
the host. However, it is still unclear whether chronic infection
has more far-reaching effects on host immunity than inducing
gallbladder inflammation, or which bacterial virulence factors
are key for colonisation. Innovative methods in diagnosing and
treating chronic carriers will be key in the elimination of enteric
fever.
While it has long been known that S. Typhi infection induces
incomplete immunity, the past decade has revealed a myriad of
ways by which S. Typhi evades the human immune response.
With the availability of new vaccine programmes to control the
disease, there will be a substantial impact on human health,
but understanding of the biology of immune evasion will be
essential to ensure eventual elimination of enteric fever from
the world.
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